All
Biologics for psoriasis: Hype and hope
March 1st 2008Along with the perils of industry support (see main story), controversies facing dermatologists include the impact of biologic drugs for psoriasis, the efficacy of treating actinic keratoses (AKs) for cancer prevention, the advancement of pay-for-performance programs, the rise in Mohs utilization rates and the role of food allergies in childhood eczema, experts say.
A complicated web: Industry relationships raise concerns, derms say
March 1st 2008It's time for dermatologists to realize the many ways in which accepting industry support can compromise patient care, an expert says. Despite mounting financial pressures, accepting industry support remains a matter of choice, he says.
Sun exposure: Do the benefits outweight the risks?
March 1st 2008The increased risk of skin cancer through exposure to sunlight, and the benefits of that exposure through enhanced production of vitamin D, were brought into sharper focus in a paper published in the Proceedings of the National Academy of Science in January.
Opinion: Derms concerned about release of of statistical data
March 1st 2008The U.S. Department of Health and Human Services is appealing a Federal Court order requiring the release of information about the number of Medicare claims filed by individual physicians. The order was the result of a Freedom of Information Act lawsuit filed by Consumers' CHECKBOOK/Center for the Study of Services, a nonprofit consumer research and information organization.
Opinion: Differences between osteopathic, allopathic derms grows "increasingly obscure'
March 1st 2008Dear Editor: I read with interest John Jesitus' December article, "M.D., D.O. Disparity," which highlighted osteopathic and allopathic dermatology education, and how differences between the two groups have become less obvious since the American Osteopathic Association (AOA) first recognized the American Osteopathic College of Dermatology (AOCD) as a subspecialty college in 1957.
Botulinum toxin in topical form draws interest
March 1st 2008Much about it is still somewhat of a mystery, but early findings on a topical form of botulinum toxin have been compelling enough to earn a $20 million show of support from Medicis and catapult the research onto the cosmetic medicine radar.
Analysis favors single-agent chemotherapy in melanoma tx
February 5th 2008London - Results of a British meta-analysis suggest that there is no evidence to support the concept that clinicians should use a combination of biological therapies and chemotherapy instead of the commonly used single-agent chemotherapy regimen for patients with metastatic melanoma, news source MedicalNewsToday.com reports.
Isolagen reports progress in nasolabial-fold therapy trials
February 5th 2008Exton, Pa. - Biotech company Isolagen announced recently that injections have been completed in the phase 3 clinical trials evaluating the Isolagen Therapy for the treatment of nasolabial folds, and that trial subjects are now in the follow-up period, PRNewswire reports.